APL-9

N/A

Report date: 2026/02/13 20:01:31
NME

Base Information

Drug NameAPL-9
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultCoronavirus Infections +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesBrazil
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesApellis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesApellis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultCoronavirus Infections +[4] 

Other Information

ATC CodeN/A
Related LinksN/A